Cuprina Holdings (Cayman) Stock
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- Singapore
- CEO
- Yong Qi Quek
- Employees
- 10
- Market cap
- $5 M
- IPO
- 10/04/2025
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly…
Cuprina Holdings (Cayman) stock: price history
1D
-2.6%
1W
+12.4%
1M
+18.7%
6M
-29.1%
YTD
-40.6%
1Y
-74.5%
2Y
–
5Y
–
10Y
–
Ask the agents about Cuprina Holdings (Cayman)
Cuprina Holdings (Cayman) stock metrics
P/E
-1.32
P/B
1.23
EV/EBITDA
-0.85
RETURN ON EQUITY
-53.2%
NET MARGIN
-10,039.2%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
34.3%
FLOAT SHARES
920,634
AVG. DAILY VOLUME (30D)
165,063
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cuprina Holdings (Cayman) stock
What does Cuprina Holdings (Cayman) do?
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Singapore.
The CEO is Yong Qi Quek, the company employs around 10 people.
The IPO was on 10/04/2025; the stock trades on NASDAQ under the ticker CUPR.
Does Cuprina Holdings (Cayman) pay a dividend?
No, Cuprina Holdings (Cayman) currently does not pay a dividend.
Which stocks are comparable to Cuprina Holdings (Cayman)?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Cuprina Holdings (Cayman) stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cuprina Holdings (Cayman) against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.